Via contract notice 2020/S 162-395132 a consortium of procurers led by Ministry of Health Turkey (MOH) launched an open tender procedure to purchase R&D services from a number of R&D providers in parallel. The aim was to compare competing alternative solution approaches to address the HSMonitor challenge. The procurement was announced to be in the form of a pre-commercial procurement (PCP) with a phased approach, i.e. a framework agreement covering 3 R&D phases:

(i) solution design;

(ii) prototype development; and

(iii) original development of limited volume of first test products/services.

Seven tenders were selected to proceed to phase I. This notice announces the tenderers which offered the best value-for-money for phase II and which were selected to proceed to phase II following a call-off. Three tenderers were offered a specific contract for phase II of the PCP.

The procurement takes the form of a pre-commercial procurement (PCP) under which R&D service contracts are awarded to R&D providers in parallel in a phased approach. This makes it possible to compare competing alternative solutions. Each selected operator is awarded a framework agreement that covers three R&D phases. For each phase, a specific contract is concluded with the selected operators. The three phases are: solution design, prototype development, original development and validation and testing of a limited volume of first products or services. After each phase, intermediate evaluations are carried out to select the best of the competing solutions. The contractors with the best value-for-money solutions are offered a specific contract for the next phase. The selected operators retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and are able to use them to exploit the full market potential of the developed solutions.